Patents by Inventor Oded Abramsky

Oded Abramsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pomegranate oil for preventing and treating neurodegenerative diseases
    Patent number: 11801220
    Abstract: The present invention relates to the use of pomegranate oil and fractions thereof for preventing and treating neurodegenerative diseases. Particularly, the present invention relates to emulsions of the pomegranate oil or fractions thereof for the prevention and treatment of brain diseases, including Creutzfeldt-Jacob disease (CJD) and multiple sclerosis (MS).
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: October 31, 2023
    Assignees: Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Ruth Gabizon, Haim Ovadia, Oded Abramsky, Shlomo Magdassi, Liraz Larush
  • POMEGRANATE OIL FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES
    Publication number: 20220339101
    Abstract: The present invention relates to the use of pomegranate oil and fractions thereof for preventing and treating neurodegenarative diseases. Particularly, the present invention relates to emulsions of the pomegranate oil or fractions thereof for the prevention and treatment of brain diseases, including Creutzfeldt-Jacob disease (CJD) and multiple sclerosis (MS).
    Type: Application
    Filed: June 29, 2022
    Publication date: October 27, 2022
    Applicants: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Ruth GABIZON, Haim Ovadia, Oded Abramsky, Shlomo Magdassi, Liraz Larush
  • Pomegranate oil for preventing and treating neurodegenerative diseases
    Patent number: 10154961
    Abstract: The present invention relates to the use of pomegranate oil and fractions thereof for preventing and treating neurodegenerative diseases. Particularly, the present invention relates to emulsions of the pomegranate oil or fractions thereof for the prevention and treatment of brain diseases, including Creutzfeldt-Jacob disease (CJD) and multiple sclerosis (MS).
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: December 18, 2018
    Assignees: Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Ruth Gabizon, Haim Ovadia, Oded Abramsky, Shlomo Magdassi, Liraz Larush
  • Pomegranate Oil For Preventing And Treating Neurodegenerative Diseases
    Publication number: 20150044314
    Abstract: The present invention relates to the use of pomegranate oil and fractions thereof for preventing and treating neurodegenerative diseases. Particularly, the present invention relates to emulsions of the pomegranate oil or fractions thereof for the prevention and treatment of brain diseases, including Creutzfeldt-Jacob disease (CJD) and multiple sclerosis (MS).
    Type: Application
    Filed: October 24, 2014
    Publication date: February 12, 2015
    Inventors: Ruth Gabizon, Haim Ovadia, Oded Abramsky, Shlomo Magdassi, Liraz Larush
  • Use of substituted quinoline carboxamide
    Patent number: 5580882
    Abstract: The use of an anti-MS quinoline-3-carboxamide compound comprising the structure of formula (I), optionally with substituents for the H.sup.1-9 hydrogen, or a salt of said compound where (a) ------------- represents that there are two conjugated double bonds between atoms comprised by the dashed line (only formula I), (b) the hydrogens H.sup.7 and H.sup.8 are attached to different atoms selected from X.sub.1, X.sub.2 and the nitrogen atom in the quinoline ring, (c) X.sub.1 and X.sub.2 are independently selected from an oxygen atom or an NH.sup.9 group, said X.sub.1 and X.sub.2 being bound by a single bond to the ring when carrying H.sub.7 or H.sub.8 and by a double bond when not carrying H.sup.7 or H.sup.8, for the manufacture of a composition intended for the treatment of conditions associated with MS. Also described are treatment regimens for MS patients. The particularly preferred compound is roquinimex or a salt thereof.
    Type: Grant
    Filed: April 8, 1994
    Date of Patent: December 3, 1996
    Assignee: Kabi Pharmacia AB
    Inventors: Oded Abramsky, Dimitrios Karussis, Dan Lehamann, Shimon Slavin